I see zero chance for PCSK9 mabs once MDCO's RNAi-based inhibitor is approved. Mabs are massively expensive, require IV administration, and have poor PD (redone every couple weeks).
It may be the case that lowering triglycerides is the 1-2 punch that results in such a massive lowering if cardiovascular disease we start calling these drugs the "heart-attack vaccines"
Of course Amgen could buy just that drug, but it's clear they love the whole sand box. They seem to be spending vast time and resources investigating RNAi, so why not bolt it on when you're sure it's ready?